SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte ...
SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a clinical stage next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene ...
Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced presentations demonstrating the clinical impact of using its flagship metagenomic ...
Generation Bio (GBIO) presented data on its cell-targeted lipid nanoparticle – ctLNP – and immune-quiet DNA – iqDNA – platforms at the European Society of Gene and Cell Therapy 31st Annual Congress.
Investor's Business Daily on MSN
Korro Bio Plummets To A Record Low On A Big Setback In RNA Editing
Korro Bio stock plummeted Thursday after its RNA-editing drug failed to pass muster in patients with a rare lung and liver ...
“High quality, large-scale, fit-for-purpose datasets” continues to be the tagline for artificial intelligence (AI) models aiming to achieve scalable drug discovery to novel targets. While troves of ...
Cabaletta Bio (CABA) announced new and updated clinical data on CABA-201 demonstrating the potential to achieve drug-free, compelling clinical responses based on eight patients dosed across the ...
DALLAS, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback